secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0000014272-24-000145
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved
--------------------------------------------------------------------------------

- Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
- Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).
- U.S. approval of Cobenfy (schizophrenia) achieved in Q3.
- Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.
- Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/0000014272-24-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/bmy-20241031.htm
  HTML page:      https://secwatch.observer/filing/0000014272-24-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer